J Diabetes Investig 2019; 10: 706--713

**Clinical Trial Registry**

*University Hospital Medical Information Network*

UMIN000015922

Introduction {#jdi12917-sec-0005}
============

Diabetic kidney disease (DKD), which is a diabetic vascular complication, is recognized as a major leading cause of end‐stage renal disease. Glucose control is fundamentally important for the prevention of DKD, as well as the control of blood pressure (BP) using renin--angiotensin system (RAS) inhibitors[1](#jdi12917-bib-0001){ref-type="ref"}. However, hypoglycemia should be avoided, because hypoglycemia is closely related to increased mortality, which is associated with an increased incidence of cardiovascular disease[2](#jdi12917-bib-0002){ref-type="ref"}, [3](#jdi12917-bib-0003){ref-type="ref"}. Treatment with dipeptidyl peptidase‐4 (DPP‐4) inhibitors, which are incretin‐related antidiabetic agents, is widely accepted in clinical practice because of their low risk of hypoglycemia and their beneficial effect on glucose control[4](#jdi12917-bib-0004){ref-type="ref"}. In addition to their glucose‐lowering effect, previous data from clinical studies showed that DPP‐4 inhibitors have renoprotective effects, which are mainly a reduction in albuminuria, independent of the glucose‐lowering effect[5](#jdi12917-bib-0005){ref-type="ref"}, [6](#jdi12917-bib-0006){ref-type="ref"}, [7](#jdi12917-bib-0007){ref-type="ref"}, [8](#jdi12917-bib-0008){ref-type="ref"}, [9](#jdi12917-bib-0009){ref-type="ref"}, [10](#jdi12917-bib-0010){ref-type="ref"}, [11](#jdi12917-bib-0011){ref-type="ref"}, [12](#jdi12917-bib-0012){ref-type="ref"}. Multiple DPP‐4 inhibitors are clinically available, and each DPP‐4 inhibitor has different features, such as chemical structure, inhibitory activity towards DPP‐4 and distribution in tissues, including the kidney. However, there are few reports regarding the difference in the renoprotective effect among DPP‐4 inhibitors. Teneligliptin has strong and long DPP‐4 inhibitory effects, and no dose adjustment may be required, even if the patient has renal function decline[13](#jdi12917-bib-0013){ref-type="ref"}, [14](#jdi12917-bib-0014){ref-type="ref"}, because 34% of the administered dose of teneligliptin is excreted unchanged through the renal route, whereas 66% is metabolized and eliminated through the hepatic and renal routes[13](#jdi12917-bib-0013){ref-type="ref"}. In addition, the distribution of teneligliptin to the kidney is high because of its lipophilicity, possibly showing a renoprotective effect. However, there are no sufficient clinical data regarding the renoprotective effect of teneligliptin in type 2 diabetes mellitus patients with DKD. Therefore, the aim of the present study was to investigate the effects of teneligliptin on glycemic control and albuminuria compared with the effects of other DPP‐4 inhibitors, in particular, by focusing on the relationship with the change of plasma DPP‐4 activity in type 2 diabetes mellitus patients with DKD.

Methods {#jdi12917-sec-0006}
=======

Participants {#jdi12917-sec-0007}
------------

A total of 40 participants with type 2 diabetes mellitus (24 men and 16 women) were selected for the present study from outpatients who visited the Department of Endocrinology and Metabolism at Kanazawa Medical University Hospital. The entry criteria included the following: (i) age ≥20 years; (ii) type 2 diabetes mellitus with a glycated hemoglobin (HbA1c) ≥6.0%; (iii) urinary albumin/creatinine (Cr) ratio (UACR) ≥30 mg/gCr in spot urine for screening of DKD; (iv) treatment with diet, exercise therapy and DPP‐4 inhibitor, excluding teneligliptin; and (v) treatment with RAS inhibitors. The exclusion criteria were as follows: (i) type 1 diabetes; (ii) severe diabetic metabolic complications, such as ketoacidosis; (iii) severe liver dysfunction; (iv) pregnant or breast‐feeding women and those who might be pregnant; and (v) any patient whom the investigator judged to be inappropriate for this study. Patients were given detailed explanations of the study protocol, and informed consent was obtained from each patient. The study protocol was approved by the ethics committee of Kanazawa Medical University. This trial was registered with the University Hospital Medical Information Network (UMIN000015922).

Study protocol {#jdi12917-sec-0008}
--------------

The present study is a single‐arm, open‐label, observational study. At the start of the study, patients were switched from other DPP‐4 inhibitors to teneligliptin 20 mg/day. Participants were assessed for several parameters at baseline and 24‐weeks after switching to teneligliptin. No changes were made to the type and dose of the glucose‐lowering agents if the participants showed hypoglycemia. RAS inhibitors, including angiotensin‐converting enzyme inhibitors or/and angiotensin II receptor blockers, were also not changed during the study period. These agents were prescribed for at least 3 months before the study.

After carrying out a screening of UACR ≥30 mg/gCr in spot urine, DKD was finally diagnosed by a UACR ≥30 mg/gCr in the first urine in the early morning. We evaluated data including the change in HbA1c, plasma DPP‐4 activity, UACR, BP and body mass index (BMI) during the treatment with teneligliptin.

Measurements {#jdi12917-sec-0009}
------------

Blood samples were collected in the morning after an overnight fast. The first urine in the early morning sample was collected at the home of participants, and the urine was carried in a cooler box to the hospital. Levels of HbA1c, plasma fasting glucose, serum total cholesterol, high‐density lipoprotein‐cholesterol and triglyceride, serum and urinary Cr, urinary albumin, serum cystatin C, urinary liver‐type fatty acid binding protein, serum aspartate transaminase, and alanine aminotransferase were measured, and the estimated glomerular filtration rate was calculated, as previously described[11](#jdi12917-bib-0011){ref-type="ref"}. Plasma DPP‐4 activity was measured by an enzymatic method, using the substrate H‐glycyl‐L‐proline‐amino‐4‐methyl coumarin hydrogen bromide (BACHEM, Inc., Bubendorf, Switzerland) and a standard amino‐4‐methyl coumarin (Sigma‐Aldrich Corp., St. Louis, MO, USA) by LSI Medience Co. (Tokyo, Japan).

Statistical analysis {#jdi12917-sec-0010}
--------------------

Statistical analyses were carried out using SAS 9.4 (SAS Institute, Cary, North Carolina, USA) by KUREHA SPECIAL LABORATORY CO., LTD. (Tokyo, Japan). All values are summarized as the mean and standard deviation. Data at baseline and 24‐weeks after switching to teneligliptin were assessed by a paired *t*‐test or Mann--Whitney *U*‐test. The correlation of two variables was analyzed by a single linear regression analysis as a Pearson correlation coefficient. Statistical significance was defined as *P *\<* *0.05.

Results {#jdi12917-sec-0011}
=======

Characteristics of the participants are shown in Table [1](#jdi12917-tbl-0001){ref-type="table"}. Initially, 40 participants who showed albuminuria of \>30 mg/gCr in spot urine were enrolled. However, 11 participants were excluded, because their albuminuria was \<30 mg/gCr in the early morning first urine. Additionally, six participants were excluded. Two participants were excluded before starting treatment with teneligliptin due to the participants' wishes, and one participant was also excluded because of a UACR \<30 mg/gCr in the spot urine, which was a mistake during the screening before starting this study. After treatment with teneligliptin, one participant declined to take teneligliptin due to an epileptic seizure, but this was not associated with teneligliptin, and one participant was excluded by doctor\'s judgement due to poor adherence to the treatment. Furthermore, because an antihypertensive agent was added during the study period, one participant was excluded. Therefore, we evaluated 23 participants for analysis in the present study. Baseline clinical characteristics, as well as concomitant background therapies, are shown in Table [1](#jdi12917-tbl-0001){ref-type="table"}. All participants received treatment with another DPP‐4 inhibitor, including linagliptin (5 mg/day, *n *=* *7), sitagliptin (100 mg/day, *n *=* *2; 50 mg/day, *n *=* *3; 25 mg/day, *n *=* *1), vildagliptin (100 mg/day, *n *=* *5), anagliptin (200 mg/day, *n *=* *3) or alogliptin (25 mg/day, *n *=* *1; 12.5 mg/day, *n *=* *1), in addition to other antidiabetic agents at baseline. Seven participants received insulin therapy. Additionally, all participants received RAS inhibitors including angiotensin‐converting enzyme inhibitors or/and angiotensin II receptor blockers, and three participants received spironolactone.

###### 

Characteristics of participants

  *n*                             23           Antihypertensive agents (*n*)   23
  ------------------------------- ------------ ------------------------------- ----
  Male:female                     13:10        RAS inhibitors (*n*)            23
  Age (years)                     68.7 ± 7.1   ARBs (*n*)                      21
  BMI (kg/m^2^)                   27.3 ± 4.4   ACEIs (*n*)                     5
  Duration of diabetes (years)    20.0 ± 8.1   ARBs + ACEIs (*n*)              3
                                               Spironolactone (*n*)            3
  Antidiabetic agents (*n*)       23           Ca‐Blockers (*n*)               10
  Sulfonylurea (*n*)              10           β‐Blockers (*n*)                1
  Glinide (*n*)                   1            α‐Blockers (*n*)                1
  Metformin (*n*)                 20           Diuretics (*n*)                 5
  α‐Glucosidase inhibitor (*n*)   2                                            
  Insulin (*n*)                   7            Antidyslipidemia agents (*n*)   17
                                               Statins (*n*)                   14
  DPP‐4 inhibitors (*n*)          23           Fibrates (*n*)                  1
  Linagliptin (*n*)               7            Ezetimibe (*n*)                 2
  Sitagliptin (*n*)               6                                            
  Vildagliptin (*n*)              5            Anti‐uric acid agents (*n*)     4
  Anagliptin (*n*)                3            Allopurinol                     2
  Alogliptin (*n*)                2            Febuxostat                      2

ACEIs, angiotensin‐converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; BMI, body mass index; DPP‐4, dipeptidyl peptidase‐4; RAS, renin--angiotensin system.
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The levels of HbA1c, FPG and other data, including UACR, renal and liver function tests, lipid data, BMI, and BP, were not significantly different after switching to teneligliptin from other DPP‐4 inhibitors (Table [2](#jdi12917-tbl-0002){ref-type="table"}). However, plasma DPP‐4 activity tended to decrease from baseline (1.49 ± 1.73 nmol/min/mL) at 8 weeks after switching to teneligliptin (0.78 ± 0.44 nmol/min/mL, *P *=* *0.139, vs baseline); and after 24 weeks, it was significantly decreased (0.57 ± 0.26 nmol/min/mL, *P *=* *0.012, vs baseline; Table [2](#jdi12917-tbl-0002){ref-type="table"}). The change rate of plasma DPP‐4 activity (Δ%DPP‐4) for 24 weeks was positively correlated with both the plasma DPP‐4 activity (*r *=* *−0.5997, *P *=* *0.0025) and FPG levels (*r *=* *−0.4235, *P *=* *0.0440) at baseline, which was evaluated by a Pearson\'s correlation coefficient analysis (Table [3](#jdi12917-tbl-0003){ref-type="table"}). However, there was no correlation between plasma DPP‐4 activity at baseline and the levels of FPG at baseline (*r *=* *0.2957, *P *=* *0.1706). The levels of HbA1c, BMI and UACR at baseline also showed no correlation to Δ%DPP‐4 (Table [3](#jdi12917-tbl-0003){ref-type="table"}). The relationship between Δ%DPP‐4 and the change rate of UACR (Δ%UACR) from the Pearson\'s correlation coefficient analysis showed a positive correlation (*r *=* *0.556, *P *=* *0.0059; Table [3](#jdi12917-tbl-0003){ref-type="table"}; Figure [1](#jdi12917-fig-0001){ref-type="fig"}a). The change amount of HbA1c (*r *=* *0.2024, *P *=* *0.3543), FPG (*r *=* *0.3960, *P *=* *0.0614), UACR (*r *=* *0.2997, *P *=* *0.1647), BMI (*r *=* *0.2943, *P *=* *0.1729), systolic BP (*r *=* *0.1940, *P *=* *0.3750) and diastolic BP (*r *=* *0.0439, *P *=* *0.1729) was not correlated to Δ%DPP‐4 at 24 weeks after switching to teneligliptin from other DPP‐4 inhibitors (Table [3](#jdi12917-tbl-0003){ref-type="table"}). There was also no significant correlation between the Δ%UACR and both plasma DPP‐4 activity (*r *=* *0.2862, *P *=* *0.1855) and FPG (*r *=* *0.2760, *P *=* *0.2024) at baseline. Furthermore, there was no significant relationship between Δ%DPP‐4 and ΔHbA1c (*r *=* *0.2024, *P *=* *0.3543; Figure [1](#jdi12917-fig-0001){ref-type="fig"}b), and between the amount of HbA1c change (ΔHbA1c) and Δ%UACR (*r *=* *0.1909, *P *=* *0.3830) at 24 weeks (Figure [1](#jdi12917-fig-0001){ref-type="fig"}c). Thus, the Δ%DPP‐4 after treatment with teneligliptin contributes to the Δ%UACR, which is independent of the change in glucose control, BMI or BP at 24 weeks, and plasma DPP‐4 activity and FPG at baseline.

###### 

Changes in laboratory data

                                        Baseline (week 0)   Week 24         *P*‐value
  ------------------------------------- ------------------- --------------- -------------------------------------------------
  HbA1c (%)                             7.82 ± 0.7          7.77 ± 0.96     0.765[\*](#jdi12917-note-0003){ref-type="fn"}
  FPG (mg/dL)                           164.7 ± 71.6        169.3 ± 71.6    0.746[\*\*](#jdi12917-note-0003){ref-type="fn"}
  Plasma DPP‐4 activity (nmol/min/mL)   1.49 ± 1.73         0.57 ± 0.26     0.010[\*\*](#jdi12917-note-0003){ref-type="fn"}
  UACR (mg/gCr)                         309.1 ± 407.1       329.2 ± 432.7   0.616[\*\*](#jdi12917-note-0003){ref-type="fn"}
  Log‐transformed UACR                  2.23 ± 0.48         2.17 ± 0.63     0.419[\*](#jdi12917-note-0003){ref-type="fn"}
  Cr (mg/dL)                            1.0 ± 0.2           1.02 ± 0.23     0.153[\*](#jdi12917-note-0003){ref-type="fn"}
  eGFRcrea (mL/min/1.73 m^2^)           54.1 ± 11.5         52.0 ± 12.4     0.250[\*\*](#jdi12917-note-0003){ref-type="fn"}
  Cystatin C (mg/L)                     1.17 ± 0.23         1.21 ± 0.25     0.263[\*](#jdi12917-note-0003){ref-type="fn"}
  eGFRcys (mL/min/1.73 m^2^)            60.4 ± 17.5         58.5 ± 17.6     0.496[\*\*](#jdi12917-note-0003){ref-type="fn"}
  Urinary L‐FABP/Cr (μg/gCr)            11.4 ± 15.2         15.4 ± 22.0     0.468[\*\*](#jdi12917-note-0003){ref-type="fn"}
  Log‐transformed urinary L‐FABP        0.80 ± 0.44         0.81 ± 0.60     0.921[\*](#jdi12917-note-0003){ref-type="fn"}
  Uric acid (mg/dL)                     5.6 ± 0.9           5.7 ± 1.1       0.638[\*\*](#jdi12917-note-0003){ref-type="fn"}
  AST (IU/L)                            22.0 ± 6.8          22.3 ± 6.3      0.933[\*\*](#jdi12917-note-0003){ref-type="fn"}
  ALT (IU/L)                            24.9 ± 14.2         24.3 ± 10.5     0.836[\*\*](#jdi12917-note-0003){ref-type="fn"}
  T‐Cho (mg/dL)                         175.3 ± 30.5        173.3 ± 32.6    0.903[\*](#jdi12917-note-0003){ref-type="fn"}
  TG (mg/dL)                            131.7 ± 55.9        150.9 ± 94.4    0.213[\*\*](#jdi12917-note-0003){ref-type="fn"}
  HDL‐C (mg/dL)                         50.6 ± 13.1         47.7 ± 10.8     0.265[\*\*](#jdi12917-note-0003){ref-type="fn"}
  BMI (kg/m^2^)                         27.4 ± 4.5          27.2 ± 4.3      0.626[\*\*](#jdi12917-note-0003){ref-type="fn"}
  Systolic BP (mmHg)                    135.2 ± 12.7        134.6 ± 13.3    0.657[\*](#jdi12917-note-0003){ref-type="fn"}
  Diastolic BP (mmHg)                   72.9 ± 8.5          73.9 ± 7.5      0.637[\*](#jdi12917-note-0003){ref-type="fn"}

Data are mean ± standard deviation. \**P*‐value, paired *t*‐test; \*\**P*‐value, Mann--Whitney *U*‐test. ALT, alanine aminotransferase; AST, aspartate transaminase; BMI, body mass index; BP, blood pressure; Cr, creatinine; DPP‐4, dipeptidyl peptidase‐4; eGFR, estimated glomerular filtration rate; eGFRcrea, serum creatinine‐based estimated glomerular filtration rate; eGFRcys, serum cystatin C‐based estimated glomerular filtration rate; FPG, fasting plasma glucose; HDL‐C, high density lipoprotein‐cholesterol; L‐FABP, liver‐type fatty acid binding protein; T‐Cho, total cholesterol; TG, triglyceride; UACR, urinary albumin/creatinine ratio.
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###### 

Relationship between changes in plasma dipeptidyl peptidase‐4 activity and various characteristics

                                                  *n*       *r*
  -------------------------------------- -------- --------- --------
  Δ%DPP‐4                                Week 0             
  HbA1c (%)                              23       −0.0760   0.7303
  FPG (mg/dL)                            23       −0.4235   0.0440
  Plasma DPP‐4 activity (nmol/min/mL)    23       −0.5997   0.0025
  UACR (mg/gCr)                          23       −0.3038   0.1588
  BMI (kg/m^2^)                          23       −0.3296   0.1342
  Changes between week 24 and baseline                      
  ΔHbA1c (%)                             23       0.2024    0.3543
  ΔFPG (mg/dL)                           23       0.3960    0.0614
  Δ%UACR                                 23       0.5560    0.0059
  ΔBMI (kg/m^2^)                         23       0.2943    0.1729
  ΔSystolic BP (mmHg)                    23       0.1940    0.3750
  ΔDiastolic BP (mmHg)                   23       0.0439    0.1729

Pearson\'s correlation coefficient. Δ%DPP‐4, change rate in level of plasma dipeptidyl peptidase‐4 activity at 24‐weeks after switching to teneligliptin; BMI, body mass index; BP, blood pressure; DPP‐4, dipeptidyl peptidase‐4; FPG, fasting plasma glucose; UACR, urinary albumin/creatinine ratio.

John Wiley & Sons, Ltd

![(a) The relationship between the change rate in urinary albumin/creatinine ratio (Δ%UACR) and plasma dipeptidyl peptidase‐4 activity (Δ%DPP‐4) at 24 weeks after switching to teneligliptin from other DPP‐4 inhibitors showed a positive correlation. (b) The relationship between Δ%DPP‐4 and the amount of glycated hemoglobin change (ΔHbA1c) at 24 weeks did not show a significant correlation. (c) The relationship between ΔHbA1c and Δ%UACR at 24 weeks did not show a significant correlation. Pearson\'s correlation coefficient analysis.](JDI-10-706-g001){#jdi12917-fig-0001}

Discussion {#jdi12917-sec-0012}
==========

The present study showed that the levels of HbA1c, FPG and other data, including UACR and lipids, showed no significant change by switching to teneligliptin from other DPP‐4 inhibitors for 24 weeks. However, the switch to teneligliptin for 24 weeks showed a significant decrease in plasma DPP‐4 activity. The decrease in plasma DPP‐4 activity by switching to teneligliptin did not contribute to an improvement in glucose control; however, we found a positive correlation between the change rate of plasma DPP‐4 activity and the change rate of UACR.

In a diabetic state, DPP‐4 activity might be enhanced[15](#jdi12917-bib-0015){ref-type="ref"}, and it is related to the pathogenesis of DKD[16](#jdi12917-bib-0016){ref-type="ref"}, [17](#jdi12917-bib-0017){ref-type="ref"}. Previous clinical studies showed that DPP‐4 inhibitors have renoprotective effects, which are mainly a reduction in albuminuria, independent of the glucose‐lowering effect[5](#jdi12917-bib-0005){ref-type="ref"}, [6](#jdi12917-bib-0006){ref-type="ref"}, [7](#jdi12917-bib-0007){ref-type="ref"}, [8](#jdi12917-bib-0008){ref-type="ref"}, [9](#jdi12917-bib-0009){ref-type="ref"}, [10](#jdi12917-bib-0010){ref-type="ref"}, [11](#jdi12917-bib-0011){ref-type="ref"}, [12](#jdi12917-bib-0012){ref-type="ref"}. In addition, Shah *et al*.[18](#jdi12917-bib-0018){ref-type="ref"} reported, in a retrospective analysis, that teneligliptin (20mg/day) for 24 weeks significantly improved glycemic control, proteinuria evaluated by urine dipstick analysis and estimated glomerular filtration rate in type 2 diabetes mellitus patients. What are the molecular mechanisms of the renoprotective effect of DPP‐4 inhibitors in the diabetic kidney? Previous reports in animal studies showed that DPP‐4 inhibitors exerted their renoprotective effect through anti‐inflammation[19](#jdi12917-bib-0019){ref-type="ref"}, [20](#jdi12917-bib-0020){ref-type="ref"}, [21](#jdi12917-bib-0021){ref-type="ref"}, anti‐oxidative stress[22](#jdi12917-bib-0022){ref-type="ref"}, [23](#jdi12917-bib-0023){ref-type="ref"}, [24](#jdi12917-bib-0024){ref-type="ref"} and anti‐fibrosis[21](#jdi12917-bib-0021){ref-type="ref"}, [23](#jdi12917-bib-0023){ref-type="ref"}, [24](#jdi12917-bib-0024){ref-type="ref"}, [25](#jdi12917-bib-0025){ref-type="ref"} activities, through glucose‐dependent or glucagon like peptide‐1 (GLP‐1) pathways via increased substrates for DPP‐4, such as GLP‐1 or stromal cell‐derived factor‐1α or substrates including a GLP‐1‐independent pathway. Additionally, teneligliptin can directly scavenge reactive oxygen species because of its structural features[26](#jdi12917-bib-0026){ref-type="ref"}. However, in the present study, the amount of albuminuria showed no significant change by switching to teneligliptin in the patients treated with RAS inhibitors, and we did not evaluate changes in the substrates for DPP‐4, including GLP‐1 and stromal cell‐derived factor‐1α, inflammation, and oxidative stress.

Multiple DPP‐4 inhibitors are available in the current clinical setting. Each DPP‐4 inhibitor has differences in chemical structure, the binding mode to DPP‐4 and their physical properties, including lipophilicity; therefore, DPP‐4 inhibitors might show differences in DPP‐4 inhibitory action on glucose control and renoprotection. However, the differences in the renoprotective effect for DKD among DPP‐4 inhibitors are unclear. In the present study, our data clearly showed that teneligliptin might have stronger inhibitory action against DPP‐4 than other DPP‐4 inhibitors, because the plasma DPP‐4 activity was significantly decreased after switching to teneligliptin. Teneligliptin has a unique structure, and binds to the S1, S2 and S2 extensive subsite of the DPP‐4 enzyme, leading to enhanced potency and selectivity, and it is also a class 3 DPP‐4 inhibitor[27](#jdi12917-bib-0027){ref-type="ref"}. Additionally, binding of teneligliptin to the S2 extensive site, apart from the S1 and S2 sites, imparts stronger inhibitory action on the DPP‐4 enzyme[28](#jdi12917-bib-0028){ref-type="ref"}. Furthermore, teneligliptin was reported to have the J‐shaped anchor‐lock domain, strong covalent bonds with DPP‐4 and more extensive S2 extensive binding, showing its higher inhibitory activity[13](#jdi12917-bib-0013){ref-type="ref"}. Plasma DPP‐4 activity mainly measures a soluble type of DPP‐4 activity; therefore, teneligliptin showed stronger inhibition of a soluble type of DPP‐4 compared with other DPP‐4 inhibitors, in the present study. However, glucose control, which was evaluated by HbA1c and FPG levels, was not changed after switching to teneligliptin, although the plasma DPP‐4 activity was reduced by teneligliptin. DPP‐4 inhibitors show a glucose‐lowering effect through increased levels of incretins, including GLP‐1, and their glucose‐lowering effect is dependent on pancreatic β‐cell function. All DPP‐4 inhibitors fundamentally have enough activity for a glucose‐lowering effect, and they show a similar effect on the reduction of HbA1c levels. Therefore, in the present study, although we could not assess changes in the levels of incretins, switching to teneligliptin from other DPP‐4 inhibitors did not lead to a greater glucose‐lowering effect. However, interestingly, we found that the change rate of plasma DPP‐4 activity is positively correlated to the change rate of UACR at 24 weeks. DPP‐4 exists in endothelial cells, tubular cells, mesangial cells and podocytes in the kidney, as a membrane‐bound type[29](#jdi12917-bib-0029){ref-type="ref"}, as well as in the blood as a soluble type. Additional studies are required to investigate the pharmacological differences between soluble and membrane‐bound DPP‐4 and to compare DPP‐4 inhibitors regarding their ability to inhibit different forms of DPP‐4. Teneligliptin has a higher lipophilicity and greater distribution to the kidney than the other DPP‐4 inhibitors, sitagliptin, alogliptin, saxagliptin, anagliptin and vildagliptin[30](#jdi12917-bib-0030){ref-type="ref"}. In addition, previously, De Nigris *et al*.[31](#jdi12917-bib-0031){ref-type="ref"} showed that teneligliptin reduces *DPP‐4* messenger ribonucleic acid and protein levels under high‐glucose conditions in cultured human vascular endothelial cells. They also showed that teneligliptin indirectly inhibits the shedding of DPP‐4 by downregulating metalloproteinase 1 (*MMP1)*,*MMP2* and *MMP14* gene expression through tumor necrosis factor‐α under hyperglycemic conditions. A decrease in these metalloproteinases reduces the release of the soluble form of DPP‐4 by human umbilical vein endothelial cells. Thus, teneligliptin might contribute to the renoprotection that was evaluated by the reduction of albuminuria in type 2 diabetes mellitus patients, associating with the suppression of both membrane bound in endothelial cells and release of soluble DPP‐4 from endothelial cells. Linagliptin also has a high lipophilicity and distribution to the kidney[30](#jdi12917-bib-0030){ref-type="ref"}, [32](#jdi12917-bib-0032){ref-type="ref"}, and a previous animal study showed the renoprotection through possibly suppressing membrane‐bound DPP‐4 in renal endothelial cells[25](#jdi12917-bib-0025){ref-type="ref"}. Additionally, several previous clinical studies have shown the renoprotective effects of linagliptin in type 2 diabetes mellitus patients[7](#jdi12917-bib-0007){ref-type="ref"}, [33](#jdi12917-bib-0033){ref-type="ref"}. In the present study, a reduction of plasma DPP‐4 activity and a positive relationship between Δ%DPP‐4 and Δ%UACR in the patients who were switched to teneligliptin from linagliptin was not observed (Table [S1](#jdi12917-sup-0001){ref-type="supplementary-material"} and Figure [S1](#jdi12917-sup-0001){ref-type="supplementary-material"}); however, the patients who were switched to teneligliptin from other DPP‐4 inhibitors, including sitagliptin, vildagliptin, alogliptin and anagliptin, showed a significant reduction of plasma DPP‐4 activity, and a positive relationship between Δ%DPP‐4 and Δ%UACR (Table [S1](#jdi12917-sup-0001){ref-type="supplementary-material"} and Figure [S1](#jdi12917-sup-0001){ref-type="supplementary-material"}). In addition, DPP‐4 inhibitors have the difference of excretion route, such as the reabsorption rate of excreted DPP‐4 inhibitor from glomeruli in tubular cells, and the hepatic or biliary route. Both teneligliptin and linagliptin have a high lipophilicity and distribution to the kidney, and teneligliptin is excreted through both the renal and hepatic route, whereas linagliptin is excreted through the biliary route. Thus, we suggest that the features of DPP‐4 inhibitor, such as lipophilicity and distribution to the kidney, might be more important for suppressing membrane‐bound DPP‐4 in the kidney, rather than the excretion route of drugs. However, further studies might be necessary to clarify the relationship between the distribution of DPP‐4 inhibitors to the kidney and the renoprotective effect by suppressing DPP‐4. In addition, the change rate of plasma DPP‐4 activity was correlated to higher plasma DPP‐4 activity and FPG levels at baseline, but there was no relationship between plasma DPP‐4 activity and FPG at baseline. Furthermore, plasma DPP‐4 activity and FPG levels at baseline showed no relationship with Δ%UACR. There was also no correlation between Δ%DPP‐4 and change in BMI and BP. Therefore, the Δ%DPP‐4 after switching to teneligliptin strongly contributes to the Δ%UACR, independently of the change in glucose control, BMI and BP, plasma DPP‐4 activity, and FPG at baseline. By contrast, Sagara *et al*.[34](#jdi12917-bib-0034){ref-type="ref"} previously showed that teneligliptin switching from sitagliptin can improve endothelial function, and reduce renal and vascular oxidative stress in patients with type 2 diabetes mellitus and CKD compared with those taking sitagliptin. The effect of teneligliptin was independent of improving glucose control, and the amount of albuminuria showed no significant difference between teneligliptin and sitagliptin treatment[34](#jdi12917-bib-0034){ref-type="ref"}. However, because they did not assess plasma DPP‐4 activity, the relationship between the change in DPP‐4 activity and UACR is unclear.

There were several limitations to the present study. This was a single‐arm, open‐label, non‐controlled study that occurred over a short time‐period, and the number of participants was small. We could not assess changes in the levels of the enzymatic substrates of DPP‐4, such as GLP‐1, stromal cell‐derived factor‐1α, oxidative stress and inflammation, after teneligliptin treatment. The detailed mechanism by which teneligliptin decreases the UACR through a reduction in DPP‐4 activity, in a glucose‐lowering independent manner, is unclear; therefore, further study is necessary to elucidate these points.

In conclusion, in the present study, switching to teneligliptin from other DPP‐4 inhibitors for 24 weeks leads to a decrease in plasma DPP‐4 activity, which is closely related to a reduction in the UACR, independently of the glucose‐lowering effect, in type 2 diabetes mellitus patients with DKD.

Disclosure {#jdi12917-sec-0014}
==========

Boehringer Ingelheim, Mitsubishi Tanabe Pharma, Kyowa Hakko Kirin, Taisho Toyama Pharmaceutical Co. and Ono Pharmaceutical Co. contributed to establishing the Division of Anticipatory Molecular Food Science and Technology. The authors declare no conflict of interest.

Supporting information
======================

###### 

**Figure S1** (a) The relationship between the change rate in urinary albumin/creatinine ratio (Δ%UACR) and plasma dipeptidyl peptidase‐4 activity (Δ%DPP‐4) at 24 weeks after switching to teneligliptin from linagliptin showed no significantly correlation (*n *=* *7). (b) The relationship between the change rate in Δ%UACR and Δ%DPP‐4 at 24‐weeks after switching to teneligliptin from other DPP‐4 inhibitors, such as sitagliptin, vildagliptin, alogliptin and anagliptin, showed a positive correlation (*n *=* *16). Pearson\'s correlation coefficient analysis.
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Click here for additional data file.
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**Table S1** Changes in plasma dipeptidyl peptidase‐4 activity.

###### 

Click here for additional data file.
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